NIH Reporter #1R21AI196558-01A1

Sleep and Adolescent Vaccine Immunogenicity: The SAVI Clinical Trial

A clinical trial investigating the impact of sleep duration on vaccine immunogenicity in adolescents, aiming to improve vaccine responses through behavioral interventions.

Description

This study aims to test whether sleep duration affects vaccine immunogenicity in adolescents aged 11-12 receiving the meningococcal vaccine. Participants will be assigned to either short sleep (7 hours) or healthy sleep (10 hours) for 7 nights, with antibody titers measured before vaccination, and 1 week and 1 month after. The primary hypothesis is that adolescents with healthy sleep will show a greater increase in antibody titers post-vaccination. Secondary measures include subjective side effects, with the expectation that the healthy sleep group will report fewer side effects. The study also explores moderators such as biological sex and examines mechanisms via biobanking serum and blood samples.

View original record